Sign in Subscribe
Scientists

Evaluation of Cationic Nanoparticles for Hepatitis B Treatment

Strategic Insights

— 1 min read

Scientists in Singapore have successfully developed a new type of cationic nanoparticle that can effectively deliver small interfering RNA (siRNA) to treat hepatitis B. The researchers created four different types of nanoparticles using biodegradable materials and evaluated their ability to deliver siRNA to liver cells. The results showed that the nanoparticles with a specific surface charge and size were able to inhibit the expression of the hepatitis B surface antigen (HBsAg) by up to 90%.

Key Takeaways:

  • The study demonstrated the potential of cationic nanoparticles as a delivery system for siRNA to treat hepatitis B.
  • The researchers created four different types of nanoparticles using biodegradable materials, including poly(lactide) (PLA) and poly(D,L-lactide-co-glycolide) (PLGA).
  • The nanoparticles were characterized in terms of size, size distribution, surface charge, and surface chemistry using techniques such as laser scattering, zeta potential measurement, and X-ray electron spectroscopy (XPS).
  • The interaction of the nanoparticles with siRNA and their ability to deliver siRNA to liver cells were evaluated using a hepatitis B model.
  • The study showed that the nanoparticles with a specific surface charge and size were able to inhibit the expression of HBsAg by up to 90%.
  • The mPEG-PLA-PEI nanoparticles demonstrated the highest inhibition effect of HBsAg expression among the four types of nanoparticles.

Statistics:

  • The researchers synthesized four groups of cationic PLA-based nanoparticles.
  • The nanoparticles were characterized in terms of size, with diameters ranging from 100 to 200 nanometers.
  • The surface charge of the nanoparticles was measured using zeta potential measurement, with values ranging from -10 to +30 millivolts.
  • The study showed that the nanoparticles with a zeta potential value of +15 millivolt were able to deliver siRNA to liver cells with the highest efficiency.
  • The inhibition effect of HBsAg expression was evaluated by measuring the HBsAg expression level, with values ranging from 50% to 90%.

Sources:

  • Wang, J., et al. (2010). Evaluation of cationic nanoparticles of biodegradable copolymers as siRNA delivery system for hepatitis B treatment. International Journal of Pharmaceutics, 400(1-2), 194-200.
  • Center for Life Sciences (published by). (2010). Gastroenterology Week. NewsRx.com.

Read more